Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL Congress

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best high short interest stocks with highest upside potential.

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate ...
Seeking Alpha

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
MedPage Today

AASLD President Highlights Major Advances in MASH Detection and Treatment

At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), AASLD President Grace L. Su, MD, of the University of Michigan in Ann Arbor, highlighted ...